Patents by Inventor Bjarne Bogen

Bjarne Bogen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12268736
    Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of heterodimer vaccine molecules formed from monomers comprising a targeting unit and a variant antigenic unit joined by heterodimerization units.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: April 8, 2025
    Assignee: University of Oslo
    Inventors: Ranveig Braathen, Bjarne Bogen
  • Publication number: 20240325519
    Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.
    Type: Application
    Filed: June 10, 2024
    Publication date: October 3, 2024
    Inventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
  • Publication number: 20240228624
    Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
    Type: Application
    Filed: September 19, 2023
    Publication date: July 11, 2024
    Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
  • Patent number: 12005112
    Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 11, 2024
    Assignee: University of Oslo
    Inventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
  • Publication number: 20240132596
    Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
    Type: Application
    Filed: September 18, 2023
    Publication date: April 25, 2024
    Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
  • Patent number: 11780924
    Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: October 10, 2023
    Assignees: UNIVERSITY OF OSLO, NYKODE THERAPEUTICS ASA
    Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
  • Publication number: 20230303718
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: February 2, 2023
    Publication date: September 28, 2023
    Applicant: NYKODE THERAPEUTICS ASA
    Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
  • Publication number: 20230065226
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 2, 2023
    Applicant: Nykode Therapeutics ASA
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Publication number: 20230048561
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: March 8, 2022
    Publication date: February 16, 2023
    Applicant: NYKODE THERAPEUTICS ASA
    Inventors: Bjarne BOGEN, Agnete B. FREDRICKSEN, Inger SANDLIE
  • Patent number: 11479605
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: October 25, 2022
    Assignee: Nykode Therapeutics ASA
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Publication number: 20220118076
    Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of heterodimer vaccine molecules formed from monomers comprising a targeting unit and a variant antigenic unit joined by heterodimerization units.
    Type: Application
    Filed: September 7, 2018
    Publication date: April 21, 2022
    Inventors: Ranveig Braathen, Bjarne Bogen
  • Publication number: 20210403572
    Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 30, 2021
    Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
  • Publication number: 20210069319
    Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 11, 2021
    Inventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
  • Publication number: 20200239568
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: February 7, 2020
    Publication date: July 30, 2020
    Applicant: Vaccibody AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Patent number: 10590195
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 17, 2020
    Assignee: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Publication number: 20180030155
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicant: Vaccibody AS
    Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
  • Patent number: 9802999
    Abstract: The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: October 31, 2017
    Assignee: VETERINAERINSTITUTTET
    Inventors: Maaike Maria Barbara Wilhelmina Dooper, Bjarne Bogen, Heidi Ragnhild Myrset
  • Patent number: 9796787
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 24, 2017
    Assignee: Vaccibody A/S
    Inventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
  • Publication number: 20160039946
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: October 1, 2015
    Publication date: February 11, 2016
    Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
  • Patent number: 9169322
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 27, 2015
    Assignee: Vaccibody AS
    Inventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie